Table 3.

Estimates of effect sizes derived from the difference-in-difference analyses.

Variable	Intervention effect	95% CI	t	p
15 anticancer western drugs
Expenditure	11105.20	[5598.80, 16611.57]	4.07	<0.001
DDDs	47.91	[33.11, 62.70]	6.5	<0.001
Bevacizumab
Expenditure	−2208.30	[−3234.49, −1182.09]	−4.3	<0.001
DDDs	8.56	[6.60, 11.06]	6.9	<0.001
Erlotinib
Expenditure	−4.91	[−124.02, 114.20]	−0.08	0.934
DDDs	1.46	[0.95, 1.96]	5.84	<0.001

CI, Confidence interval.